Dabrafenib is a selective inhibitor of mutant B-RafV600E (IC50 = 0.8 nM), with 4- and 6-fold reduced potency against wild type B-Raf and c-Raf (IC50 = 3.2 and 5 nM, respectively).1 Has been in clinical trials in patients with B-RafV600E metastatic melano
* VAT and and shipping costs not included. Errors and price changes excepted